LEVODOPA/CARBIDOPA GPPL 250/25 levodopa 250 mg and carbidopa (as monohydrate) 25 mg tablet bottle

Land: Ástralía

Tungumál: enska

Heimild: Department of Health (Therapeutic Goods Administration)

Virkt innihaldsefni:

carbidopa monohydrate, Quantity: 27 mg (Equivalent: carbidopa, Qty 25 mg); levodopa, Quantity: 250 mg

Fáanlegur frá:

Arrotex Pharmaceuticals Pty Ltd

Lyfjaform:

Tablet, uncoated

Samsetning:

Excipient Ingredients: crospovidone; indigo carmine aluminium lake; microcrystalline cellulose; pregelatinised maize starch; magnesium stearate

Stjórnsýsluleið:

Oral

Einingar í pakka:

100 tablets

Gerð lyfseðils:

(S4) Prescription Only Medicine

Ábendingar:

LEVODOPA/CARBIDOPA GPPL is indicated for the treatment of Parkinson's disease and syndrome. It is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia. LEVODOPA/CARBIDOPA GPPL frequently is helpful in the management of tremor, dysphagia, sialorrhoea and postural instability associated with Parkinson's disease and syndrome.

Vörulýsing:

Visual Identification: Round, light blue uncoated tablets with 'C' on one side and '20' on the other side.; Container Type: Bottle; Container Material: HDPE; Container Life Time: 12 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

Leyfisstaða:

Registered

Leyfisdagur:

2018-01-11